Skip to main content
. 2021 Mar 8;2(3):685–701. doi: 10.1039/d1cb00023c

Fig. 6. PET/CT images from the phase I clinical trial of 68Ga-anti-HER2-Nanobody in breast cancer patients. (A) Patient 18, with invaded lymph nodes in the mediastinum and left hilar region. (B) Patient 20, with bone metastasis in the pelvis. PET/CT images (top) and PET images (bottom). Adapted from ref. 97.

Fig. 6